Indian drugmaker Alembic Pharmaceuticals Limited has secured final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Prucalopride Tablets, 1 mg and 2 mg. The generic drug targets chronic idiopathic constipation, addressing an estimated $100 million U.S. market.
VADODARA, India — Indian pharmaceutical major Alembic Pharmaceuticals Limited announced on July 28, 2026, that it has received final regulatory approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Prucalopride Tablets, in 1 mg and 2 mg strengths. The regulatory decision allows the company to manufacture and market the therapeutic equivalent of Takeda Pharmaceuticals USA Inc.'s reference listed drug, Motegrity. The clearance marks a major commercial milestone for Alembic as it expands its gastrointestinal product offerings in the United States, targeting an established prescription market evaluated at $100 million for the twelve months ending March 2026.
Therapeutic Application and Market Dynamics
Prucalopride is a selective serotonin-4 (5-HT4) receptor agonist engineered to stimulate colonic muscle motility, facilitating bowel movements in adult patients suffering from chronic idiopathic constipation (CIC). Chronic idiopathic constipation is a prevalent gastrointestinal disorder affecting a substantial portion of the adult population globally, often presenting persistent symptoms that remain unresponsive to standard over-the-counter laxative treatments.
According to market intelligence data cited from IQVIA in Alembic's regulatory disclosure, Prucalopride Tablets (1 mg and 2 mg) generated an estimated annual market size of US$ 100 million in the United States for the twelve-month period ending March 2026. The grant of the Alembic Pharma Prucalopride Approval provides American healthcare providers and patients with an additional bioequivalent generic alternative to brand-name Motegrity, potentially lowering prescription drug costs for long-term constipation management.
Cumulative ANDA Portfolio and Manufacturing Operations
With this latest approval, Alembic Pharmaceuticals has amassed a cumulative total of 245 ANDA approvals from the USFDA, comprising 225 final approvals and 20 tentative approvals. The company manufactures its generic formulations across state-of-the-art production facilities in India, which undergo periodic inspections by international regulatory agencies, including the USFDA, to ensure compliance with Current Good Manufacturing Practice (cGMP) standards.
The successful Alembic Pharma Prucalopride Approval underscores the integrated research and development capabilities of the company's Vadodara-based headquarters. As a publicly traded pharmaceutical enterprise listed on Indian exchanges, Alembic operates a global distribution network supported by extensive clinical development pipelines and a domestic branded field workforce of over 5,500 personnel across India.
Strategic Implications for Investors and Consumers
For healthcare consumers and retail pharmacies in the U.S. market, the commercial availability of generic prucalopride tablets is expected to enhance supply chain stability and foster price competition within the prescription gastrointestinal category. Generic drugs approved via the USFDA ANDA pathway undergo rigorous bioequivalence and pharmaceutical quality testing to demonstrate identical therapeutic performance to the reference listed drug.
For equity investors following the pharmaceutical sector, the Alembic Pharma Prucalopride Approval reflects steady execution in Alembic's U.S. generic product launch cadence. Expanding its basket of specialized oral solid dosage formulations remains central to sustaining revenue growth amidst pricing pressures in mature overseas pharmaceutical markets.
Official Sources Section
All regulatory metrics, product specifications, and corporate details contained in this report originate directly from official press announcements and regulatory notifications submitted by Alembic Pharmaceuticals Limited to stock exchanges.
Primary corporate details were verified against filings hosted on the official portals of the National Stock Exchange of India and BSE India. Regulatory standards and drug approval frameworks were referenced via the official guidelines of the U.S. Food and Drug Administration and corporate disclosures on the Alembic Pharmaceuticals Portal.
Quote Section
In reviewing corporate pipeline developments and regulatory clearances, company disclosures emphasized compliance and portfolio expansion:
"According to officials and regulatory releases, the final clearance for Prucalopride Tablets, 1 mg and 2 mg, reflects the company's ongoing commitment to delivering high-quality bioequivalent generic medicines to international markets while strengthening its overall ANDA portfolio," corporate filings stated.
Why It Matters
The receipt of the Alembic Pharma Prucalopride Approval carries notable practical implications for healthcare delivery and market competition:
Cost Accessibility: Introduces a competitive generic alternative to Motegrity, helping lower prescription expenses for adult patients with chronic idiopathic constipation.
Pipeline Momentum: Bolsters Alembic’s USFDA portfolio, bringing its total generic approvals to 245 ANDA filings.
Market Expansion: Enables Alembic to capture market share within a $100 million U.S. gastrointestinal therapeutic segment.
Key Facts at a Glance
Drug Product: Prucalopride Tablets, 1 mg and 2 mg.
Indication: Treatment of chronic idiopathic constipation (CIC) in adult patients.
Reference Listed Drug: Motegrity Tablets (Takeda Pharmaceuticals USA Inc.).
Estimated Market Size: US$ 100 million for the 12 months ending March 2026, according to IQVIA data.
Total Approvals: Alembic holds 245 cumulative ANDA approvals (225 final, 20 tentative) from the USFDA.
FAQ Section
Q1: What is Prucalopride used for?
A1: Prucalopride is a selective serotonin-4 (5-HT4) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adult patients who require motility stimulation.
Q2: What did the USFDA approve for Alembic Pharmaceuticals?
A2: The USFDA granted final approval for Alembic’s Abbreviated New Drug Application (ANDA) for Prucalopride Tablets in 1 mg and 2 mg dosage strengths, establishing therapeutic equivalence to Motegrity.
Q3: What is the estimated market size for Prucalopride Tablets in the United States?
A3: According to IQVIA data cited in corporate disclosures, Prucalopride Tablets had an estimated U.S. market size of US$ 100 million for the twelve months ending March 2026.
Q4: How many USFDA approvals does Alembic Pharmaceuticals hold?
A4: Following the latest Alembic Pharma Prucalopride Approval, Alembic holds a cumulative total of 245 ANDA approvals from the USFDA, including 225 final approvals and 20 tentative approvals.
Source: National Stock Exchange of India, BSE India, U.S. Food and Drug Administration, Alembic Pharmaceuticals Portal
